NAMS

NewAmsterdam Pharma Company N.V.NASDAQHealthcare

$32.99+0.55%ClosedMarket Cap: $3.79B

As of 2026-04-06

Recent Analyst Ratings

Date	Firm	Action	Rating	Previous
2026-02-19	Guggenheim	—	Buy	—
2026-02-18	Needham	—	Buy	—
2026-01-21	RBC Capital	—	Outperform	—
2025-12-16	Stifel	—	Buy	—
2025-12-02	Goldman Sachs	—	Neutral	—
2025-11-06	RBC Capital	—	Outperform	—
2025-11-05	Needham	—	Buy	—
2025-10-17	Citigroup	—	Buy	—
2025-08-07	RBC Capital	—	Outperform	—
2025-06-12	Needham	—	Buy	—

Forward Estimates

Period	EPS Est.	Revenue Est.	# Analysts
Fri Dec 31	$-1.39	$159.6M	8
Sun Dec 31	$-0.21	$381.7M	7
Mon Dec 31	$1.59	$720.3M	6
Tue Dec 31	$3.66	$1.08B	6